What was the Women's Health Initiative E+P trial?

The WHI E+P was a large randomized controlled trial that tested whether daily combined estrogen (CEE 0.625 mg) plus progestin (MPA 2.5 mg) would prevent heart disease in 16,608 postmenopausal women aged 50, 79. It was stopped early in 2002 after finding that the hormones increased risks of heart attack, breast cancer, stroke, and blood clots.

Why was the WHI E+P trial stopped early?

The Data Safety Monitoring Board stopped the trial after 5.2 years (of a planned 8.5) because the breast cancer hazard ratio crossed a pre-specified safety boundary and the overall balance of risks versus benefits, as measured by a global index, was unfavorable.

How much did breast cancer risk increase in the WHI?

Women taking CEE + MPA had a 26% relative increase in invasive breast cancer (HR 1.26 to 95% CI 1.00, 1.59). In absolute terms, this translated to about 8 extra cases per 10,000 women per year of use. The increased risk became apparent after approximately four years of hormone use.

Were the women in the WHI too old to represent typical HRT users?

The average age was 63, and roughly two-thirds were over 60. Most typical HRT users start around age 51 for menopausal symptoms. This age mismatch is a valid criticism and led to the "timing hypothesis," which suggests that starting hormones earlier in menopause may carry a different risk profile.

Does the WHI apply to bioidentical hormones or transdermal estrogen?

The WHI tested only oral conjugated equine estrogens with medroxyprogesterone acetate. It did not test transdermal estradiol or micronized progesterone. Whether these alternatives carry the same risks, particularly for VTE and breast cancer, is an active area of research but has not been settled by a comparable large RCT.

Did HRT increase death rates in the WHI?

No. All-cause mortality was nearly identical between the two groups during the trial (HR 0.98 to 95% CI 0.82, 1.18). Extended follow-up through 18 years also showed no significant mortality difference, meaning the excess cardiovascular and cancer events did not translate into a measurable increase in overall deaths.

What benefits did the WHI find for combined HRT?

CEE + MPA significantly reduced hip fractures (34% reduction) and colorectal cancer (37% reduction). These benefits were real but numerically outweighed by the increases in cardiovascular events and breast cancer when the population was primarily older postmenopausal women.

How did the WHI change HRT prescribing?

HRT prescriptions dropped roughly 50% within two years of the 2002 publication. FDA labeling was updated with boxed warnings. Current guidelines now recommend HRT for symptomatic women under 60 or within 10 years of menopause at the lowest effective dose, rather than as a long-term preventive strategy.

What is the timing hypothesis from the WHI?

The timing hypothesis proposes that HRT started near menopause onset (before significant atherosclerosis develops) may be cardiovascularly neutral or protective, while HRT started years later may increase cardiac risk. Age-stratified WHI data support this pattern, but no large RCT has definitively confirmed it.

Is it safe to take HRT today based on the WHI results?

For symptomatic women under 60 or within 10 years of menopause, major medical societies consider HRT appropriate at the lowest effective dose for the shortest needed duration. The WHI results primarily caution against using combined HRT as a preventive medicine strategy in older, asymptomatic women.

WHI E+P Trial: A Plain-English Overview of What It Established

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Detail | Value | |---|---| | Trial name | Women's Health Initiative Estrogen + Progestin (WHI E+P) | | N | 16,608 | | Intervention | Conjugated equine estrogens (CEE) 0.625 mg/day + medroxyprogesterone acetate (MPA) 2.5 mg/day | | Comparator | Matching placebo | | Duration | Planned 8.5 years; stopped at mean 5.2 years | | Primary endpoints | Coronary heart disease (benefit hypothesis) and invasive breast cancer (primary safety outcome) | | Key result | Hazard ratio for CHD 1.29 (95% CI 1.02, 1.63); HR for invasive breast cancer 1.26 (95% CI 1.00, 1.59). Global index unfavorable. Trial halted early by the Data Safety Monitoring Board. |

The Question the Trial Asked

By the late 1990s, observational data (most prominently the Nurses' Health Study) suggested that postmenopausal hormone therapy protected the heart. Millions of women took HRT not just for hot flashes but as a long-term preventive strategy. The WHI set out to test that assumption with the gold standard: a large, multicenter, double-blind, placebo-controlled randomized trial.

The E+P arm specifically asked whether daily combined CEE + MPA would reduce coronary heart disease events in healthy postmenopausal women aged 50 to 79. Breast cancer was designated the primary safety outcome because earlier data already hinted at a possible link between long-term combined HRT and breast malignancy.

Who Was Enrolled

Participants were 16,608 postmenopausal women with an intact uterus, recruited from 40 U.S. clinical centers between 1993 and 1998. Key enrollment characteristics:

Age range: 50, 79, with a mean of 63.3 years. Roughly two-thirds were over 60 at enrollment.
Ethnic composition: 83.9% White, 6.8% Black, 5.4% Hispanic, and 3.9% other groups.
Baseline health: Women with a prior breast cancer diagnosis were excluded. Those with pre-existing cardiovascular disease were not, though the majority had no history of CHD.
BMI: The mean was approximately 28.5 kg/m², and over one-third of participants were obese.

A detail often missed in media coverage: most enrollees were a decade or more past menopause. They were not the typical 51-year-old starting HRT for hot flashes. This age distribution became central to later reinterpretation of the findings.

What They Received

Randomization assigned 8,506 women to active treatment and 8,102 to placebo. The active regimen was a single daily tablet containing CEE 0.625 mg plus MPA 2.5 mg (marketed as Prempro). The dose was fixed; there was no titration.

Adherence declined over time. By year 5, roughly 42% of women assigned to active treatment had stopped taking study pills. In the placebo group, about 10.7% initiated open-label hormone therapy on their own. These crossover rates dilute any treatment signal, meaning the true biological effect of the hormones may be larger than the intention-to-treat analysis captured.

What Was Measured

The trial tracked a "global index" of seven outcomes, balancing expected benefits against potential harms:

WHI E+P Global Index: Outcome Classification Framework

Hypothesized benefits (expected to decrease)

Coronary heart disease (MI, coronary death)
Hip fracture
Colorectal cancer

Monitored risks (expected to potentially increase)

Invasive breast cancer
Stroke
Pulmonary embolism
Endometrial cancer (monitored but not indexed, since MPA was added specifically to prevent it)

Global-index rule: If the overall weighted harm, benefit balance crossed a pre-specified boundary, the DSMB could recommend stopping. That is exactly what happened.

What the Trial Found

The DSMB halted the E+P arm on July 7, 2002, after a mean follow-up of 5.2 years. Below are the primary outcome results as reported in the 2002 JAMA publication.

Annualized Absolute Rates per 10,000 Person-Years

| Outcome | CEE + MPA | Placebo | Hazard Ratio (95% CI) | Excess or Fewer Events per 10,000 Women-Years | |---|---|---|---|---| | Coronary heart disease | 37 | 30 | 1.29 (1.02, 1.63) | +7 | | Invasive breast cancer | 38 | 30 | 1.26 (1.00, 1.59) | +8 | | Stroke | 29 | 21 | 1.41 (1.07, 1.85) | +8 | | Pulmonary embolism | 16 | 8 | 2.13 (1.39, 3.25) | +8 | | Colorectal cancer | 10 | 16 | 0.63 (0.43, 0.92) | −6 | | Hip fracture | 10 | 15 | 0.66 (0.45, 0.98) | −5 | | Death (all cause) | 52 | 53 | 0.98 (0.82, 1.18) | −1 (NS) |

The breast cancer hazard ratio crossed nominal significance only in the final analysis. Over the full 5.2-year follow-up, 166 cases of invasive breast cancer occurred in the hormone group versus 124 in the placebo group.

Putting the Numbers in Perspective

The absolute excess risk was small on an individual level. For every 10,000 women taking CEE + MPA for one year, there were roughly 7 extra heart attacks, 8 extra invasive breast cancers, 8 extra strokes, and 8 extra pulmonary emboli, offset by 6 fewer colorectal cancers and 5 fewer hip fractures.

At a population scale, however, these numbers are large. Tens of millions of women were using HRT at the time. Even a small per-person risk, multiplied across that population, translates into thousands of excess cardiovascular events and cancers annually.

Cardiovascular Results: The Surprise

The entire premise of the trial was that hormones would protect the heart. Instead, CHD risk rose by 29%. The increase appeared early (within the first year) and did not disappear with longer use. This pattern was consistent with the earlier HERS trial, which had also failed to show cardiac benefit in women with existing heart disease.

Stroke risk increased by 41%, a finding that was statistically significant and consistent across subgroups. Venous thromboembolism risk more than doubled, the largest relative increase of any outcome in the trial.

Breast Cancer Results

The 26% relative increase in invasive breast cancer emerged gradually and became apparent after about four years of use. The cancers diagnosed in the hormone group tended to be slightly larger and more likely to be node-positive at detection, raising concern that hormones might not just promote tumor growth but also delay diagnosis by increasing mammographic breast density.

Later follow-up through 2010, published as part of the WHI extended analysis, showed that the breast cancer excess persisted even after women stopped hormones. The post-intervention follow-up at a cumulative 11 years reported a sustained and statistically significant increase in breast cancer incidence and, for the first time, a statistically significant increase in breast cancer mortality in the CEE + MPA group.

What the Trial Got Right

Scale and rigor. At 16,608 women across 40 centers, with blinded randomization and adjudicated endpoints, this was the definitive test of combined HRT for chronic disease prevention.
Pre-specified stopping rules. The DSMB acted on pre-defined boundaries, not post-hoc alarm.
Long follow-up. Even after early stopping, extended surveillance continued for over a decade, generating some of the most complete post-trial safety data in preventive medicine.

What Critics Have Identified as Limitations

Several criticisms emerged in the years after publication. Some are methodologically valid. Others are overstated.

Age at enrollment. The mean age was 63. Only 3,167 women (about 19%) were aged 50, 54, the group most representative of women starting HRT at menopause. Critics argue that starting hormones in older women with years of estrogen deprivation may carry different risks than starting them in early menopause. The "timing hypothesis" (discussed below) grew directly from this concern.

Single dose, single formulation. The trial tested one dose of one estrogen (CEE 0.625 mg) combined with one progestogen (MPA 2.5 mg). It did not test lower doses, transdermal estradiol, micronized progesterone, or other regimens now commonly used. Whether the findings apply to these alternatives remains debated. Current Endocrine Society guidelines acknowledge that different formulations may carry different risk profiles, particularly for VTE and possibly breast cancer.

Adherence erosion. With 42% of the active group discontinuing pills and 10.7% of the placebo group starting outside hormones, the intention-to-treat analysis underestimates the true biological effect. This cuts both ways: true risks and true benefits were both likely larger than measured.

Global index weighting. The composite endpoint weighted all events equally, treating a hip fracture the same as a fatal PE. Some clinicians argue this obscured individual risk-benefit tradeoffs for specific outcomes.

The Timing Hypothesis and Later Reanalysis

Post-hoc age-stratified analyses, including the WHI age-stratified reanalysis, found a different pattern in younger women. Among those aged 50, 59 at enrollment (closer to menopause), the CHD hazard ratio was 1.11 with a confidence interval crossing 1.0, meaning no statistically significant increase. The trend even suggested possible benefit in the youngest subgroup.

This gave rise to the "timing hypothesis": that starting HRT close to menopause, before atherosclerosis has advanced, might be neutral or beneficial for the heart, while starting it a decade later might promote events on already-diseased arteries.

The timing hypothesis is plausible, supported by biological models, primate studies, and consistent subgroup trends. But it has not been proven in a dedicated randomized trial in younger women, and the WHI was not designed or powered to test it. The KEEPS and ELITE trials provided supportive but not definitive evidence.

Impact on Clinical Practice

The WHI E+P publication on July 17, 2002 triggered one of the sharpest prescribing shifts in modern medicine. Within two years, HRT prescriptions in the United States dropped by roughly 50%. Many women stopped hormones abruptly, often without medical guidance. Some physicians refused to prescribe any form of HRT at all.

Over the following two decades, the clinical consensus has recalibrated. Current FDA labeling for estrogen-progestin products requires a boxed warning about cardiovascular and breast cancer risks, citing the WHI directly. At the same time, major societies including the North American Menopause Society and the Endocrine Society now endorse hormone therapy for symptomatic women under 60 or within 10 years of menopause, using the lowest effective dose for the shortest necessary duration.

The WHI did not prove that all hormone therapy is dangerous for all women. It proved that one specific regimen, at one specific dose, given primarily to older women, increased several serious risks at rates that outweighed measurable benefits when used for chronic disease prevention. That distinction matters.

Ongoing Relevance

The WHI remains the largest and most cited trial in menopausal hormone therapy research. Its extended follow-up data continue to inform guidelines. The cumulative mortality analysis through 18 years of follow-up, published in 2017, showed no significant difference in all-cause mortality between the hormone and placebo groups during the full post-intervention period, a finding that somewhat tempered the initial alarm.

For clinicians today, the WHI's core lesson is specific: combined CEE + MPA should not be used as a preventive strategy against heart disease in older postmenopausal women. For younger symptomatic women, the decision involves a different risk-benefit calculation that the WHI was not designed to answer.

Frequently asked questions

›

References

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333. PubMed
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS). JAMA. 1998;280(7):605-613. PubMed
Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692. PubMed
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. PubMed
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. PubMed
FDA. Prempro (conjugated estrogens/medroxyprogesterone acetate) prescribing information. FDA Label